论文部分内容阅读
采用抗ＣＤ３单抗（１０μｇ／ｍｌ）联合ＩＬ－２（５０Ｕ／ｍｌ）诱导肿瘤病人外周血单个核细胞成为ＣＤ３ＡＫ细胞，并观察其体外增殖及抗肿瘤作用，结果显示：肿瘤病人的ＮＫ活性显著低于正常人，但其ＣＤ３ＡＫ细胞体外杀伤Ｋ５６２细胞的细胞毒活性与正常人比较无明显差异（Ｐ＞００５）。本研究初步表明：由肿瘤病人外周血单个核细胞诱导的ＣＤ３ＡＫ细胞，可作为过继免疫治疗的效应细胞进行自身淋巴细胞治疗
Anti-CD3 monoclonal antibody (10 μg/ml) combined with IL-2 (50 U/ml) was used to induce CD3AK cells from peripheral blood mononuclear cells of tumor patients. The proliferation and anti-tumor effects were observed in vitro. The results showed that the NK activity of tumor patients was significant. However, the cytotoxic activity of CD3AK cells against K562 cells in vitro was not significantly different from that of normal people (P>005). This study preliminary showed that: CD3AK cells induced by peripheral blood mononuclear cells from tumor patients can be used as adoptive immunotherapy effector cells for autologous lymphocyte therapy